Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid

Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorDr. Anne Conlin

About this trial

Nosebleeds are very common, occurring in 60% of the population; in some patients, nosebleeds are a life-threatening emergency. To stop a nosebleed in the emergency department, doctors usually have to burn the nose (called cauterization) or insert pledgets (called nasal packing) into the nose to apply direct pressure to the bleeding site. Nasal packing can cause pain and discomfort at the time it is inserted in the nose and again when it is removed. In rare cases it can cause a range of complications: minor complications include scar bands in the nose, but serious complications of nasal packing have also occurred, including death. Nasal packing can also present risks to doctors, such as the risk of contracting airborne and bloodborne infections, like COVID-19 and HIV.

Tranexamic acid in pill form or given directly into a vein is a medication that is currently used for nosebleeds. This study looks to evaluate if tranexamic acid in powder form sprayed directly in the nose can be used as an alternative to cauterization or nasal packing for the treatment of nosebleeds.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Capable of giving informed consent form

Stated willingness to comply with all study procedures and availability for the duration of the study

Adults 18 years or older

Male or female

Disqualifiers

Prior sinonasal surgery within the preceding 1 month.

Patients who required medical treatment for epistaxis in the preceding 30 days.

Septum perforation.

Known history of bleeding disorders, including thrombocytopenia, hemophilia, hereditary hemorrhagic telangiectasia, or von Willebrand disease.

Trial design

Design model

Single group

Treatments tested in this trial

  • Tranexamic Acid

    Drug

    Tranexamic acid powder intranasally

Treatment groups

24 Participants
are divided into 1 treatment group
Group A: Tranexamic acid powder applied intranasallyExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Cessation of epistaxis

Number of participants for whom epistaxis ceased after treatment

Time frame
Day 1

Secondary outcomes

1

Time to cessation of epistaxis

Measured in minutes

Time frame
Day 1
2

Pain of the treatment

Participants' perception of pain will be measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain possible).

Time frame
Day 1
3

Total time in the Emergency Department

Measured in minutes

Time frame
Day 1
4

Number of participants who returned to the Emergency Department for treatment of epistaxis

Time frame
within the first 24 hours and the first 5 days after treatment

Other outcomes

1

Age

Time frame
Day 1
2

Anticoagulant and/or antiplatelet medication use

Time frame
Day 1
3

Type of epistaxis

Anterior versus posterior epistaxis

Time frame
Day 1
4

Adverse events and/or patient-reported side effects

Time frame
up to 3 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dr. Anne Conlin

Lead sponsor

Peterborough Regional Health Centre

Sponsor institution

University of Ottawa

Collaborator